

Gynecology Oncology (GynOnc) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

BASKET

UCI 24-146

REGN5668 + REGN4018 or Cemiplimab
Coord: Jiana Ejbara
Accrual: 1/5

UCI 24-08

SPEDOX-6 for 2L+ cervical or ovarian
Coord: Jiana Ejbara
Accrual: 3/25

MUTATIONS

UCI 23-186

Long-term safety and efficacy of
Pembrolizumab
Coord: Jiana Ejbara
Accrual: 1/8

UCI 24-144

SCG142 T Cell Receptor
Targeting HPV16/HPV52
Coord: Jiana Ejbara
Accrual: 0/5

COGNITIVE FUNCTION

UCI 24-05

Riluzole
Coord: Jiana Ejbara
Accrual: 15/26

PLATINUM-RESISTANT RECURRENCE

>3L

GOG-3076

Platinum Doublet + Bevacizumab +/-OlviVec
 Coord: Jiana Ejbara
 Accrual: 2/5

PLATINUM-SENSITIVE RECURRENCE

FRa + and >1L

GOG-3078

Mirvetuximab Soravtansine
 Coord: Jiana Ejbara
 Accrual: 1/5

GOG 3119

Pembro +/- Sacituzumab Tirumotecan
Coord: Jiana Ejbara
Accrual: 0/5

GOG 3110

AZD8205 (ADC) vs. Physicians Choice
for B7-H4 positive endo
Coord: Jiana Ejbara
Accrual: 0/5

OVARIAN CANCER

UCI 21-190

Assessing the Predictive Capability of Circulating
Tumor DNA as a Screening Tool for Ovarian
Cancer

ctDNA

Coord: Jiana Ejbara

Accrual: 2/36